Contribution of TLR4 Signaling in Intermittent Hypoxia-mediated Atherosclerosis Progression
Overview
General Medicine
Affiliations
Background: Intermittent hypoxia (IH), a typical character of obstructive sleep apnea (OSA), is related to atherogenesis. However, the role of IH on atherosclerosis (AS) progression and the mechanisms involved remains poorly understood.
Methods: In the present study, high-fat fed ApoE mice were treated with recombinant shRNA-TLR4 lentivirus and exposed to IH. Atherosclerotic lesions on the en face aorta and cross-sections of aortic root were examined by Oil-Red O staining. The content of lipids and collagen of aortic root plaques were detected by Oil-Red O staining and Sirius red staining, respectively. The TLR4, NF-κB p65, α-SMA and MOMA-2 expression in aorta and IL-6 and TNF-α expression in the mice serum were also detected.
Results: Compared with the Sham group, the IH treated group further increased atherosclerotic plaque loads and plaque vulnerability in the aortic sinus. Along with increased TLR4 expression, enhanced NF-κB activation, inflammatory activity and aggravated dyslipidemia were observed in the IH treated group. TLR4 interference partly inhibited IH-mediated AS progression with decreased inflammation and improved cholesterol levels. Similarly, in endothelial cells, hypoxia/reoxygenation exposure has been shown to promote TLR4 expression and activation of proinflammatory TLR4/NF-κB signaling, while TLR4 interference inhibited these effects.
Conclusions: We found that the IH accelerated growth and vulnerability of atherosclerotic plaque, which probably acted by triggering the activation of proinflammatory TLR4/NF-κB signaling. These findings may suggest that IH is a risk factor for vulnerable plaque and provide a new insight into the treatment of OSA-induced AS progression.
Antioxidant and Anti-Inflammatory Effects of Bioactive Compounds in Atherosclerosis.
Rosian S, Boarescu I, Boarescu P Int J Mol Sci. 2025; 26(3).
PMID: 39941147 PMC: 11818840. DOI: 10.3390/ijms26031379.
Gong Z, Yang H, Gao L, Liu Y, Chu Q, Luo C BMC Complement Med Ther. 2025; 25(1):28.
PMID: 39871254 PMC: 11770944. DOI: 10.1186/s12906-025-04760-x.
Polecka A, Nawrocki J, Pulido M, Olszewska E J Clin Med. 2024; 13(22).
PMID: 39597901 PMC: 11594591. DOI: 10.3390/jcm13226757.
Bagheri B, Khatibiyan Feyzabadi Z, Nouri A, Azadfallah A, Mahdizade Ari M, Hemmati M Mediators Inflamm. 2024; 2024:5830491.
PMID: 38445291 PMC: 10914434. DOI: 10.1155/2024/5830491.
Ziliene E, Inciura A, Ugenskiene R, Juozaityte E Diagnostics (Basel). 2023; 13(12).
PMID: 37370894 PMC: 10297714. DOI: 10.3390/diagnostics13121999.